Background: Two novel systemic inflammation indices, SII and SIRI, are associated with increased risk of cardiovascular diseases (CVD). However, SII and SIRI are prone to change over time and the association between changeable status and long-term outcome risk remains to be uncovered. This study aims to examine the association between the dynamic status of SII and SIRI and risk of CVD. Methods: This prospective study included a total of 45,809 subjects without MI, stroke and cancer prior to or in 2010 (baseline of this study). The dynamic status of SII and SIRI during 2006, 2008, and 2010 was assessed by dynamic trajectories (primary exposure), annual increase, and average value. The outcome was CVD incidence during 8.6 years' follow-up. Multiple Cox regression models were used to calculate the adjusted hazard ratios (HRs) and confidence intervals (95% CIs). Results: Four dynamic trajectories of SII and SIRI were identified as follows: low stable pattern, moderate stable pattern, increase pattern, and decrease pattern. For SII, compared with "low stable pattern", after controlling confounders and level of SII in 2006, adjusted HRs were 1.24 (95% CI = 1.02-1.51) for "increase pattern" and 1.11 (95% CI = 1.00-1.23) for "moderate-stable pattern" while the association was not significant for "decrease pattern". Additionally, the highest group of annual SII increase and average SII had respective HR of 1.20 (95% CI = 1.05-1.37) and 1.32 (95% CI = 1.13-1.55). The results were consistent for SIRI. "Increase pattern" and "moderate stable pattern" increased the risk of CVD by 38% (HR = 1.38, 95% CI = 1.17-1.63) and 12% (HR = 1.12, 95% CI = 1.01-1.25), while no significant association was found for "decrease pattern". The highest group of annual SIRI increase and average SIRI had respective HR of 1.25 (95% CI = 1.09-1.44) and 1.39 (95% CI = 1.19-1.63). Conclusion: Dynamic status of SII and SIRI was significantly associated with risk of CVD, which highlighted that we should focus on the dynamic change of SII and SIRI.
Background: Traditional blood lipids play an important role in diabetes and cardiovascular diseases, but the evidences were not enough . The lipoprotein indices of low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C) ratios may be the predictive parameters to diabetes and cardiovascular disease. Methods: A 6-year follow-up study was performed in 22,649 subjects (were aged 18–95 years old) without a history of cardiovascular disease (CVD) or diabetes. The information about cardiovascular disease and T2DM was extracted from the Disease Surveillance Points (DSP) system in 2019. Biochemical and demographic variables were acquired by laboratory test and the face-to-face interview with structured questionnaire, the response rate was 88.9%. Lipid ratios were stratified by tertile to ascertain the hazard ratio (HR) of diseases by Cox proportional hazard model. Results: The mean age of subjects was 54.9(14.5) years, 41.9% were males. LDL-C /HDL-C was strongly associated with coronary heart disease (CHD) ( second vs. first tertile: HR, 1.86; 95% CI, 1.03-3.37, p =0.04 ; third vs. first tertile: HR, 3.29; 95% CI, 1.91-5.69, p< 0.001), meanwhile the TG/HDL-C was specifically associated with type 2 diabetes mellitus (T2DM) (second vs. first tertile: HR, 1.56; 95% CI, 1.2-2.02, p =0.001; third vs. first tertile: HR, 2.7; 95% CI, 2.13-3.43, p< 0.001). Moreover, the HR, of diseases was increased with LDL-C, TG/HDL-C ratios. The results of sensitivity analysis revealed the associations of LDL-C, TG/HDL-C ratios with CHD and T2DM were independent on confounders. Conclusion: Our findings suggested that the LDL-C/HDL-C ratio and TG/HDL-C ratio associated with CHD and T2DM , and hazard ratio of disease increased with lipoprotein derived indices.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.